Trial Profile
Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Sulfonylurea in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 05 Oct 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 23 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.